GLG Pharma ^Companies

GLG Pharma is an organization focused on personalized medicine for oncology using STAT3 inhibitors and a novel cancer culture called Gx-C3. They have obtained worldwide licenses to develop and market pharmaceuticals derived from STAT3 inhibitor technology, which is considered a promising approach to treating various cancers. GLG Pharma has started clinical trials for chronic lymphocytic leukemia and plans to conduct trials for triple negative breast cancer and ovarian cancer. They have also developed a new technology called Gx-C3, which allows cancer cells to behave in the laboratory as if they were still in the body, leading to patient-centered personalized treatment protocols. Additionally, GLG Pharma's STAT3 inhibitors have shown the ability to reverse resistance in cancer cells and they have a line of repurposed drugs that can be quickly moved to clinical trials.